8AK Stock Chart & Stats
€46.64
-€0.30(-0.64%)
At close: 4:00 PM EDT
€46.64
-€0.30(-0.64%)
Day’s Range― - ―
52-Week Range€22.00 - €48.28
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€7.11B
Enterprise Value€10.01K
Total Cash (Recent Filing)€656.58M
Total Debt (Recent Filing)€1.57B
Price to Earnings (P/E)124.5
Beta0.66
Next Earnings
Oct 28, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.40
Shares Outstanding167,763,280
10 Day Avg. Volume8
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)2.53
Price to Sales (P/S)3.12
P/FCF Ratio9.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€50.31Price Target Upside7.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.42
Revenue Forecast (FY)€1.58B
Bulls Say, Bears Say
Bulls Say
Proprietary Product Sales Grew 34% YoY To $411.7M In Q2 2026Strong growth across psychiatry, addiction and LUMRYZ demonstrates effective commercialization and expanding product contribution. If sustained, the broader proprietary portfolio can reduce reliance on legacy royalties and support a more durable revenue base.
Orexin Pipeline Has Advanced Clinical Momentum And Potential Exclusivity BenefitsLate-stage progress, positive durability data and orphan designations strengthen the pipeline’s strategic value. Successful development could add differentiated neuroscience revenue, while regulatory incentives may improve exclusivity and development economics.
Positive Cash Generation And Diversified Manufacturing And Royalty RevenuePositive free cash flow provides internal funding for clinical programs, debt service and commercial investment. Manufacturing and royalty revenue adds diversification beyond proprietary products, helping support resilience across product-cycle changes.
Bears Say
Leverage Increased Sharply, With Debt Of Approximately $1.57B And Debt-to-equity Near 0.87The step-up in leverage reduces financial flexibility and increases sensitivity to interest costs while the company funds pipeline and integration spending. Although equity remains sizable, higher debt raises execution risk if profitability or cash generation weakens.
TTM Profitability Deteriorated As Net Margin Fell To Approximately 4%The sharp margin decline makes earnings quality less predictable and limits retained cash available for investment. Elevated R&D and acquisition-related SG&A may create long-term value, but they currently increase the time and execution required to restore profitability.
LYBALVI Gross-to-net Pressure And Future Orexin Competition Threaten Commercial EconomicsHigher rebates and discounts can dilute incremental LYBALVI sales, while an earlier competing orexin launch could influence pricing, reimbursement and physician adoption. These pressures may reduce the revenue and margin benefits of portfolio expansion.
Alkermes News
8AK FAQ
What was Alkermes’s price range in the past 12 months?
Alkermes lowest stock price was €22.00 and its highest was €48.28 in the past 12 months.
What is Alkermes’s market cap?
Alkermes’s market cap is €7.11B.
When is Alkermes’s upcoming earnings report date?
Alkermes’s upcoming earnings report date is Oct 28, 2026 which is in 68 days.
How were Alkermes’s earnings last quarter?
Alkermes released its earnings results on Jul 28, 2026. The company reported €0 earnings per share for the quarter, beating the consensus estimate of -€0.023 by €0.023.
Is Alkermes overvalued?
According to Wall Street analysts Alkermes’s price is currently Undervalued.
Does Alkermes pay dividends?
Alkermes does not currently pay dividends.
What is Alkermes’s EPS estimate?
Alkermes’s EPS estimate is -0.03.
How many shares outstanding does Alkermes have?
Alkermes has 167,763,280 shares outstanding.
What happened to Alkermes’s price movement after its last earnings report?
Alkermes reported an EPS of €0 in its last earnings report, beating expectations of -€0.023. Following the earnings report the stock price went down -1.012%.
Which hedge fund is a major shareholder of Alkermes?
Currently, no hedge funds are holding shares in DE:8AK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alkermes Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€50.31 (7.87% Upside)
€50.31 (7.87% Upside)
Blogger Sentiment
Bullish
DE:8AK Sentiment 75%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €2.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
101.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
95.01%
Trailing 12-Months
Company Description
Alkermes
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
8AK Company Deck
8AK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful clinical progress, particularly across the orexin franchise and the successful integration of Avadel/LUMRYZ. Key revenue and access wins (proprietary sales +34% YoY, LYBALVI access >80%, LUMRYZ patient growth +25% YoY) and robust pipeline readouts (alixorexton LTE durability, Positive LUMRYZ Phase 3, multiple orexin programs advancing) underpin optimism. Offsetting items include margin pressure from expanding gross-to-net (LYBALVI), a substantial increase in R&D and SG&A tied to pipeline advancement and acquisition integration, a contingent consideration charge that pushes the GAAP loss guidance negative, and competitive/pricing uncertainty from other orexin entrants. Overall, the positive commercial and clinical developments outweigh the cost and near-term margin headwinds.View all DE:8AK earnings summaries8AK Revenue Breakdown
89.69% U.S.
10.24% Rest of world
0.07% Ireland
8AK Stock 12 Month Forecast
Average Price Target
€50.31
▲(7.87% Upside)